About Samsung BioLogics
Samsung BioLogics is a company based in Incheon (South Korea) founded in 2011.. The company has 5,010 employees as of December 31, 2024. Samsung BioLogics has completed 2 acquisitions, including Human Genome Sciences and Samsung Bioepis. Samsung BioLogics operates in a competitive market with competitors including Novartis, Catalent, Surrozen, Biotage and Curia, among others.
- Headquarter Incheon, South Korea
- Employees 5010 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Samsung Biologics Co., Ltd.
-
Annual Revenue
$3.16 B (USD)0.21as on Dec 31, 2025
-
Net Profit
$1.11 B (USD)49.02as on Dec 31, 2025
-
EBITDA
$1.3 B (USD)19.69as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
5010
as on Dec 31, 2024
-
Investments & Acquisitions
Human Genome Sciences
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Samsung BioLogics
Samsung BioLogics is a publicly listed company on the KRX with ticker symbol 207940 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Sales and Marketing
31 people
Leadership Team
22 people
Senior Team
17 people
Software Development Team
15 people
Lead Team
7 people
Human Resources and Administration
7 people
Product Management Team
5 people
Group Team
5 people
Unlock access to complete
Funding Insights of Samsung BioLogics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Samsung BioLogics
Samsung BioLogics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Human Genome Sciences and Samsung Bioepis. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of biosimilar drugs for the treatment of multiple diseases
|
2012 | ||||
|
Gene-based drugs for lupus, hepatitis C, inhalation anthrax and cancer.
|
1992 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Samsung BioLogics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Samsung Biologics Comparisons
Competitors of Samsung BioLogics
Samsung BioLogics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Surrozen, Biotage and Curia, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
|
| domain | founded_year | HQ Location |
CDMO offering drug and biologics development services
|
|
| domain | founded_year | HQ Location |
Selective Wnt agonists are developed for human tissue regeneration.
|
|
| domain | founded_year | HQ Location |
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
|
|
| domain | founded_year | HQ Location |
Drug research, development, testing, and consulting services are provided.
|
|
| domain | founded_year | HQ Location |
Provides contract research, development, and manufacturing services for biologic drugs.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Samsung Biologics
Frequently Asked Questions about Samsung BioLogics
When was Samsung BioLogics founded?
Samsung BioLogics was founded in 2011.
Where is Samsung BioLogics located?
Samsung BioLogics is headquartered in Incheon, South Korea.
How many employees does Samsung BioLogics have?
As of Dec 31, 2024, the latest employee count at Samsung BioLogics is 5,010.
What is the annual revenue of Samsung BioLogics?
Annual revenue of Samsung BioLogics is $3.16B as on Dec 31, 2025.
What does Samsung BioLogics do?
Samsung BioLogics was established in 2011 in Incheon, South Korea. Services as a contract development and manufacturing organization (CDMO) in the biologics sector are offered by the company. Development and production of biologic pharmaceuticals are handled, with operations based in South Korea. Global pharmaceutical clients are supported through these manufacturing capabilities, focusing on biopharmaceutical processes and quality standards.
Who are the top competitors of Samsung BioLogics?
Is Samsung BioLogics publicly traded?
Yes, Samsung BioLogics is publicly traded on KRX under the ticker symbol 207940.
How many acquisitions has Samsung BioLogics made?
Samsung BioLogics has made 2 acquisitions, including Human Genome Sciences, and Samsung Bioepis.
What is Samsung BioLogics's ticker symbol?
The ticker symbol of Samsung BioLogics is 207940 on KRX.